Black Diamond Therapeutics, Inc (BDTX)

Black Diamond Therapeutics, Inc's Q·Score is 8.3/10 (Bullish), reflecting its current fundamentals, analyst data, and valuation metrics. High-quality business with 23% return on equity and 32% profit margins. This is an informational data summary only and does not constitute financial advice. Always do your own research before making any investment decision.

The consensus price target for BDTX is $9.86, based on ratings from 7 Wall Street analysts. This is 279.1% above the current price of $2.60. Price targets are forward-looking estimates and not guarantees of future performance.

Black Diamond Therapeutics, Inc (BDTX) scores in line with sector averages on valuation metrics. The consensus analyst price target of $9.86 is 279% above the current price.

Black Diamond Therapeutics, Inc is scheduled to report earnings in 8 days, on May 11, 2026.

Black Diamond Therapeutics, Inc has a net profit margin of 32.0%, which is considered high and reflects strong pricing power. Its gross margin stands at 100.0%, indicating a high-margin business model.

Black Diamond Therapeutics, Inc has a debt-to-equity ratio of 0.17×, reflecting a very low debt-to-equity ratio, signalling a conservatively financed balance sheet. Its current ratio is 8.42×, indicating comfortable short-term liquidity.